세계의 가상 임상시험 시장 - 시험 디자인별, 유형별, 단계별, 적응증별, 산업별 예측(2024-2032년)

Virtual Clinical Trials Market size is projected to expand at 7.1% CAGR from 2024 to 2032. The advancements in digital health technologies and telemedicine are enabling remote data collection, monitoring, and patient engagement while reducing the need for physical site visits and lowering overall costs. To that end, virtual trials have grown largely popular as they offer greater accessibility and convenience for participants, leading to improved patient recruitment, retention, and diversity.

In October 2023, Elligo Health Research collaborated with Avallano to introduce myTrialsConnect, an AI-driven clinical trial recruitment and engagement platform, allowing patients to participate in trials and connect with healthcare providers network. Similar innovations by leading players will positively influence the industry growth.

Additionally, several regulatory agencies are increasingly supporting virtual trial approaches for providing clearer guidance and frameworks. The growing importance of virtual trials in facilitating real-time data analysis and decision-making for enhancing the efficiency and speed of clinical research processes will add to the industry growth.

The virtual clinical trials market is segregated into study design, type, phase, indication, industry, and region.

Based on study design, the market size from the observational segment will expand at 6.7% growth rate from 2024 to 2032. Rapid advancements in digital technologies is enabling remote collection of data, making it easier to conduct observational studies without the need for physical site visits. Virtual observational studies offer greater convenience for participants, leading to improved recruitment and retention rates. The ability to collect real-world data in real-time is also enhancing the validity and reliability of study findings.

In terms of industry, the virtual clinical trials market from the medical devices companies segment is estimated to rise at 7.2% CAGR through 2032. The advancements in remote monitoring technologies is enabling medical device companies to conduct trials more efficiently. Virtual trials reduce the logistical burden associated with traditional trials, ensuring faster and more cost-effective research. The regulatory support for virtual trial methodologies will further boost the segment growth.

Regionally, the Asia Pacific virtual clinical trials industry will showcase significant growth at 7.6% CAGR from 2024 to 2032. The increasing adoption of digital health technologies is facilitating remote data collection and patient engagement in the region. The rising demand for decentralized trial approaches is improving accessibility and diversity of participants. The rollout of supportive regulatory frameworks and guidelines are encouraging the adoption of virtual trial methodologies. Lately, the onset of the COVID-19 pandemic has also accelerated the shift towards virtual trials across APAC for ensuring continuity of research amid restrictions on in-person interactions.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Technological advancements in virtual clinical trials
    • 3.2.1.2 Rising penetration of technology in healthcare
    • 3.2.1.3 Development of novel medications for various diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Study Design, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Interventional
• 5.3 Observational
• 5.4 Expanded access

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Fully virtual trials
• 6.3 Hybrid virtual trials

Chapter 7 Market Estimates and Forecast, By Phases, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Phase I
• 7.3 Phase II
• 7.4 Phase III
• 7.5 Phase IV

Chapter 8 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 CNS
• 8.3 Autoimmune/inflammation
• 8.4 Cardiovascular disease
• 8.5 Metabolic/endocrinology
• 8.6 Infectious disease
• 8.7 Oncology
• 8.8 Genitourinary
• 8.9 Ophthalmology
• 8.10 Other indications

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Contract research organizations (CROs)
• 9.4 Medical devices companies
• 9.5 Other industries

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Clinical Ink
• 11.2 CROPRIME Ltd
• 11.3 ICON, plc
• 11.4 IQVIA Inc.
• 11.5 Medable, Inc.
• 11.6 Medidata
• 11.7 Oracle Corporation
• 11.8 Parexel International (MA) Corporation
• 11.9 PRA Health Sciences
• 11.10 Signant Health